News &amp; Updates

No excess CV risk with febuxostat vs allopurinol for gout: FAST study

04 Feb 2021 by

Using the urate-lowering drug febuxostat does not come with an excess risk of major cardiovascular (CV) events compared with allopurinol for gout treatment, according to the EMA*-mandated post-authorization safety study, FAST**.

No excess CV risk with febuxostat vs allopurinol for gout: FAST study

Beta blockers plus diuretic tied to lowest SBP in OSA patients

Obstructive sleep apnoea (OSA) patients on antihypertension medication often have poorly controlled blood pressure (BP), reveals a study. Treatment with beta blockers alone or in combination with a diuretic appears to result in the lowest systolic (S)BP in this clinical cohort.

Beta blockers plus diuretic tied to lowest SBP in OSA patients

Cerebral microbleeds predict adverse cardiac, cerebrovascular events in CAD patients

The presence of cerebral microbleeds is associated with major adverse cardiac and cerebrovascular events in patients with coronary artery disease (CAD) on antithrombotic treatment, a study has found.

Cerebral microbleeds predict adverse cardiac, cerebrovascular events in CAD patients

Exenatide once weekly falls short of reducing carotid plaque progression in T2D

The long-acting glucagon-like peptide 1 receptor agonist exenatide once weekly helps improve glycaemic control but does little to modify carotid plaque volume or composition in patients with type 2 diabetes (T2D), according to the results of a trial.

Exenatide once weekly falls short of reducing carotid plaque progression in T2D

Original New Drug Application Approvals by US FDA (16 - 31 January 2021)

02 Feb 2021

New drug applications approved by US FDA as of 16-31 January 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 January 2021)

02 Feb 2021

Remote management by allied HCP an option post-MI

01 Feb 2021 by

Low-risk patients who have undergone revascularization following an acute myocardial infarction (MI) could potentially be managed with allied healthcare practitioner (HCP)-led remote intensive management (RIM), according to results of the Singapore-based IMMACULATE* trial.

Remote management by allied HCP an option post-MI

Haemoglobin drop ups death risk in hospitalized ACS patients

01 Feb 2021 by

In-hospital decreases in haemoglobin (Hb) levels ≥3 g/dl is prevalent among patients with acute coronary syndrome (ACS) managed invasively and appears to increase the risk for 1-year mortality even in the absence of overt bleeding, according to a study.

Haemoglobin drop ups death risk in hospitalized ACS patients

Vasomotor symptoms a female-specific CVD risk factor

Frequent and persistent vasomotor symptoms confer about a 50–77-percent increased risk of developing subsequent cardiovascular disease (CVD), a study has found.

Vasomotor symptoms a female-specific CVD risk factor